Angiogenesis-related pathways in the pathogenesis of ovarian cancer - sprookjes - yvandenbroek - TriplyDB

Angiogenesis-related pathways in the pathogenesis of ovarian cancer

Angiogenesis-related pathways in the pathogenesis of ovarian cancer

http://www.wikidata.org/entity/Q37139109

about

Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer Molecular therapy of colorectal cancer: progress and future directions Precision targeted therapy of ovarian cancer Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation Critical role of histone demethylase RBP2 in human gastric cancer angiogenesis.Role of nerve growth factor and its TRKA receptor in normal ovarian and epithelial ovarian cancer angiogenesis.Ovarian cancer-related hypophosphatemic osteomalacia--a case report.Highly effective antiangiogenesis via magnetic mesoporous silica-based siRNA vehicle targeting the VEGF gene for orthotopic ovarian cancer therapy PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer.New ways to successfully target tumor vasculature in ovarian cancer.Mechanisms and Targets Involved in Dissemination of Ovarian Cancer.In vitro and in vivo antiangiogenic activity of desacetylvinblastine monohydrazide through inhibition of VEGFR2 and Axl pathways Chemokine receptors in epithelial ovarian cancer Ovarian cancer biology and immunotherapy.FGFs: crucial factors that regulate tumour initiation and progression.Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician.Prediction of therapy response in ovarian cancer: Where are we now?Abnormalities in alternative splicing of angiogenesis-related genes and their role in HIV-related cancers.Biological Pathways Involved in Tumor Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special References to Ovarian Cancer.The Proangiogenic Capabilities of Malignant Ascites Generated by Aggressive Ovarian Tumors.Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes.The metabolic cross-talk between epithelial cancer cells and stromal fibroblasts in ovarian cancer progression: Autophagy plays a role.Sphingosine kinase 1/sphingosine-1-phosphate (S1P)/S1P receptor axis is involved in ovarian cancer angiogenesis.Modeling angiogenesis with micro- and nanotechnology.Tumor-secreted anterior gradient-2 binds to VEGF and FGF2 and enhances their activities by promoting their homodimerization.The peritoneal "soil" for a cancerous "seed": a comprehensive review of the pathogenesis of intraperitoneal cancer metastases.Immunotherapeutic Targeting of Tumor-Associated Blood Vessels.Primary non-Hodgkin lymphoma of the right femur and subsequent metastasis to the left femur: A case report and literature review.Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer.A randomized, crossover phase 1 study to assess the effects of formulation (capsule vs tablet) and meal consumption on the bioavailability of dovitinib (TKI258).

P2860

Q26777453-783013C0-0D3D-46D4-83C7-5BF9D5F87112 Q27005764-E53B8A40-97C3-41F6-9D98-334B701C8F60 Q28078658-56AB50B4-42AC-4A68-961D-4B42D34866F7 Q31138109-BF01BFC9-4038-47F4-8E37-D1FFA8EA1905 Q33960142-EE27BC2D-778F-44E8-84E5-30D9EFCDBE0E Q34579082-9D8C71C9-AEC7-4CEC-B04A-E977CC0A07A4 Q34628431-1F2284E2-ECCE-4C56-B1BA-1AF60E0C95D4 Q35284618-42A7FE61-9077-4DD8-A0AE-0C0861EED9FB Q35470322-DB7AC1A6-80BC-4138-AE13-63A39C662554 Q35670576-A4D1D095-A241-482D-863D-7A86A5BD66B0 Q35928220-80D02B7C-BEC9-492D-B203-45F3FC464383 Q36180735-FDC5FE8F-A3D0-4CBB-93D3-A99A633BAEE7 Q36879511-FB1306D9-BB6F-4506-97C6-BDA920995B10 Q37535454-E4C4713D-8FEB-4A8F-A41A-702FFC891148 Q38218761-9B758C5C-BF12-4C8A-849C-01612EA89354 Q38887615-08D0B655-4B4A-41F8-A7A2-78D31DCEB8ED Q39233197-45EBF763-C4D2-4005-85B9-8E898BA4B895 Q39263260-838442EE-720C-4A68-90AD-7ED7FCF95FD4 Q39426973-3B1CB265-6908-408F-8344-F9F4489CF44C Q41660578-2972E453-5974-4941-BB52-396BFAC06545 Q42709077-688826B0-8760-4C07-9F24-D13DB6E709E6 Q46083075-785387CF-1846-429F-831B-296E0E896E1E Q46304569-D58DB874-C38D-44ED-9705-86F78DCD3078 Q46726983-1751F2A6-4C17-4B31-8057-692A80626D86 Q47598622-897E4256-0798-4195-9395-089ED179EB75 Q47898529-ABCAF25E-C825-45E4-8974-696E81FDD6A8 Q48278671-107CF906-6A88-4401-B631-57EB4C968CF9 Q49592831-B9A229FD-1234-4A0E-AD34-C1B92CAB518D Q52655152-F4DA8028-4FCC-464B-B408-B274A5454DD4 Q52941950-E5D5945F-1CFE-464D-A5D6-A4660DBEF885 Q53620524-2A9EE745-40B7-404C-AD09-B52D5DD82DCF

P2860

Angiogenesis-related pathways in the pathogenesis of ovarian cancer

http://www.wikidata.org/entity/Q37139109

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 30 July 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Angiogenesis-related pathways in the pathogenesis of ovarian cancer

@en

Angiogenesis-related pathways in the pathogenesis of ovarian cancer.

@nl

type

label

Angiogenesis-related pathways in the pathogenesis of ovarian cancer

@en

Angiogenesis-related pathways in the pathogenesis of ovarian cancer.

@nl

prefLabel

Angiogenesis-related pathways in the pathogenesis of ovarian cancer

@en

Angiogenesis-related pathways in the pathogenesis of ovarian cancer.

@nl

P1433

Q37139109-02E23286-5F2B-4E40-A1BE-17537AFCB0BE

P1476

Q37139109-D31B11DD-D2B8-4290-93F9-8A6A25FED993

P2093

Q37139109-21C8AE68-61B2-4736-B652-290573F19355

Q37139109-667F8251-D220-487E-B880-8C022E5A3461

Q37139109-708B1313-DB81-4329-A345-2E508F35E96A

Q37139109-7E46541B-B324-44E0-AA29-5D76D72AA845

Q37139109-9341B566-4289-4B54-8840-83D1053D4937

Q37139109-96F3D99A-D801-4D58-9ECB-5F364E3FE715

Q37139109-DE8F1E68-C9AB-4651-A87E-CB80580C98A8

P275

Q37139109-D2D14432-73CF-4DC3-ABB6-12704D3D4D1A

P2860

Q37139109-028B5878-39E6-4EF0-8619-41E62AB3A93D

Q37139109-07FF895C-6EA7-4AA3-BF7E-A6CD84EF2C00

Q37139109-0AEFADF7-7F0B-4402-B110-2214C46CC052

Q37139109-0BFAB18B-31BD-40F4-B1F2-622EC87B0EF1

Q37139109-0C743ADF-E7FB-4DCD-9D9C-00F84415E81F

Q37139109-0CA50014-BE70-446B-899F-E9395FB2AD90

Q37139109-0DE7F6E6-FA74-4FE3-8099-ABBF0A6A5028

Q37139109-100A52E1-AF56-44A5-AB7D-FC4A20D18213

Q37139109-1046BCD6-238B-4B18-BA2A-9A061083E773

Q37139109-11ABC124-D68A-488A-8EEE-16B518E9A9E4

P304

Q37139109-33DC21D1-BD94-4E36-A939-6D70E449AE74

P31

Q37139109-0EF37F22-AB8C-45A7-9528-172BF598444C

Q37139109-A4684349-5B71-49BC-A5DD-B9FD7AE523F6

P356

Q37139109-0CC6F5DE-4A45-40DD-8E92-5E217D5CE298

P407

Q37139109-30E926BB-AB5C-4A7F-AF1E-D8E4AE5C3E83

P433

Q37139109-05C54ADD-5A0C-4A4D-9701-DBBA89437E11

P478

Q37139109-15806D17-701E-4D17-957B-E8A6A91442FF

P50

Q37139109-1B02F814-0DE6-46AD-A4AE-602C7313DA2A

P5008

Q37139109-21258BC7-117C-43D8-ACB8-63DD8DC69695

P577

Q37139109-A73D0E4F-E720-41F1-91AA-392E26A0AF7C

P5875

Q37139109-ED468CE7-A7C6-4AA7-B73E-9D0215A7F621

P698

Q37139109-DA10F43D-BAE5-42CD-8423-307A148B22A6

P921

Q37139109-69D2A3BB-06B3-4253-9599-0624937DD481

Q37139109-84CF324B-7651-44FC-97BD-2AB78E33975E

Q37139109-A25ED004-AD0E-4C99-811F-BE5D61EE250F

P932

Q37139109-295465A1-9D46-4A3E-9243-08B120625BD0

P356

P1433

International Journal of Molecular Sciences

P1476

Angiogenesis-related pathways in the pathogenesis of ovarian cancer

@en

P2093

Aristotle Bamias

http://www.w3.org/2001/XMLSchema#string

Calliope Arapinis

http://www.w3.org/2001/XMLSchema#string

Christine Liacos

http://www.w3.org/2001/XMLSchema#string

Michalis Liontos

http://www.w3.org/2001/XMLSchema#string

Nikos G Gavalas

http://www.w3.org/2001/XMLSchema#string

Sofia-Paraskevi Trachana

http://www.w3.org/2001/XMLSchema#string

Tina Bagratuni

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 3.0 Unported

P2860

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium

VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development

The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor

A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases

Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy

Cancer statistics, 2012

Tumor angiogenesis: therapeutic implications

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

P304

15885-15909

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3390/IJMS140815885

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

Meletios A. Dimopoulos

P5008

P577

2013-07-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

254260163

http://www.w3.org/2001/XMLSchema#string

P698

23903048

http://www.w3.org/2001/XMLSchema#string

P921

ovarian neoplasm

P932

3759892

http://www.w3.org/2001/XMLSchema#string